GLG Webinar: Navigating Southeast Asia Market Access Strategies for Chinese Pharma Companies
The wave of Chinese pharmaceutical companies expanding into the U.S. market is slowing, while the potential and opportunities in Southeast Asia continue to emerge. What are the basic processes and key considerations for pharmaceutical companies entering the Southeast Asian market? How are leading pharmaceutical firms currently progressing in their strategic layouts? What are the market prospects for popular drugs?
GLG (Gerson Lehrman Group) cordially invites decision-makers in the fields of pharmaceutical innovation and global expansion to participate in a public online webinar scheduled for August 28, Beijing Time. Professor Rui Guozhong, Vice Chairman of the China Association for Promotion of Technology Entrepreneurship and Secretary-General of the Biomedical Park Working Committee, and Dr. Chen Bo, Distinguished “Huazhong Excellent Scholar” Professor at Huazhong University of Science and Technology and Director of the Free Trade Zone Research Center, have been invited to attend the conference. They will provide an in-depth analysis of strategies for Chinese pharmaceutical companies expanding into Southeast Asia, jointly exploring and sharing the advantages and successful case studies of “pharmaceutical global expansion,” including:
Strategic Analysis of Pharmaceutical Market Registration and Listing in Southeast Asia: Macroeconomic Environments, Access Policies, Potential in Key Markets Such as Singapore and Malaysia, and Key Considerations
The Trend of Investing and Establishing Factories in Singapore: Site Selection and Evaluation
Market Entry and Process Strategies for Pharmaceutical Companies Expanding into Southeast Asia: In-House Development, Joint Ventures, M&A, and Licensing Models
Current Landscape of Leading Pharmaceutical Companies’ Strategic Deployments and Classic Cases of Overseas Product Expansion: Focusing on Chia Tai Tianqing, Akeso, Junshi Biosciences, Innovent Biologics, and Other Enterprises; PD-1 Monoclonal Antibodies, ADC Drugs, and Various Vaccines
GLG Public Online Webinar: Featured Guest Profile
Prof. Rui Guozhong
Senior Expert in Pharmaceutical Technology, Economics, and Management in China
Professor Rui Guozhong currently serves as Vice Chairman of the China Technology Entrepreneurship Association and Secretary-General of its Biomedical Park Working Committee. He is also the Chairman and Founder of Torch Guokang (Beijing) Pharmaceutical Technology Co., Ltd., Beijing Huachuang Yangguang Pharmaceutical Technology Development Co., Ltd., Shanghai Fengxian Biotechnology Development Co., Ltd., and Nanjing Tianyin Guokang Biomedical Technology Development Co., Ltd. With 35 years of extensive experience in biomedical innovation, technology transfer, commercialization, and industrialization, Professor Rui has participated in and facilitated numerous pharmaceutical companies, research institutions, and investors in successfully completing clinical trials, drug registration, technology assessment and transfer, as well as hundreds of financing rounds and project mergers and acquisitions. Professor Rui holds a Bachelor’s degree in Public Health from Nanjing Medical University, a Master’s degree in Health Services Management (Health Economics) from the Health Science Center of Peking University, and an EMBA in Sci-Tech Innovation Management from Tsinghua University.
Dr. Bo Chen
Currently holds the title of “Huazhong Distinguished Scholar” at Huazhong University of Science and Technology
Distinguished Professor and Director of the Free Trade Zone Research Center
Dr. Chen Bo served as Deputy Director of the Department of World Economics and Trade, Secretary-General of the Institute of Free Trade Zones, and Doctoral Supervisor at the School of International Business Administration, Shanghai University of Finance and Economics, from September 2008 to August 2016. Dr. Chen’s primary research interests include international trade, the Chinese economy, and regional economic cooperation. He is also a senior lecturer invited by the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council, delivering lectures and training programs for executives of central and state-owned enterprises on topics such as China’s macroeconomic landscape and the development of the Belt and Road Initiative. Professor Chen concurrently serves as a Visiting Fellow at the Federal Reserve Bank of Dallas and as a Distinguished Advisor to the Jack Austin Centre in Canada. Recently, Dr. Chen has conducted in-depth research on bidirectional open innovation policies in the healthcare and pharmaceutical sectors. He has produced specialized research reports on feasible pathways for cross-border e-commerce of over-the-counter (OTC) drugs and the introduction of foreign-funded medical research and diagnostic centers in regions such as the Suzhou Industrial Park and the Wuhan East Lake High-Tech Development Zone.
Scan the QR code / Click to read the full article
Register for the event:
GLG Group
Gathering Professional Insights to Empower Excellent Decision-Making
GLG Gerson Lehrman Group is committed to building a global knowledge-sharing platform.
We match business decision-makers who require professional insights with industry experts possessing firsthand experience, empowering them to make decisions with clearer objectives and greater confidence. Our globally leading network of experts aggregates diverse, primary-source expertise, and we onboard hundreds of new experts into our panel every day.
Click to view the GLG official website
Since its founding 25 years ago, GLG (Gerson Lehrman Group) has aggregated cutting-edge insights in specialized fields through expert interviews, conferences and events, and custom research services. By precisely aligning with research directions, GLG empowers leading global investment firms and pharmaceutical companies to make exceptional business decisions across sectors including medical devices, diagnostics, life sciences, pharmaceuticals, and biotechnology.
GLG Expert Insights | Changes in Pharmaceutical Policies and Their Impact on the Market